Streamlining EmblemHealth Skyrizi Prior Authorization Workflows
Navigating EmblemHealth Skyrizi prior authorization demands a precise understanding of payer-specific criteria and workflow nuances. Klivira automates this complex process, ensuring efficiency and compliance.
For revenue cycle directors and prior authorization coordinators, managing specialty drug approvals like Skyrizi (risankizumab) with EmblemHealth can be a significant operational bottleneck. This page details the specific considerations for securing timely approvals, from formulary placement to step therapy protocols, and how automation can alleviate administrative burden.
EmblemHealth Formulary Placement for Skyrizi (risankizumab)
As an IL-23 inhibitor, Skyrizi (risankizumab) is typically classified as a specialty medication on EmblemHealth's formulary, often residing on a higher tier (e.g., Tier 4 or 5). This placement consistently triggers prior authorization requirements, quantity limits, and often step therapy protocols, underscoring the need for meticulous documentation and submission.
Prior Authorization Requirements for EmblemHealth Skyrizi
EmblemHealth's prior authorization process for Skyrizi is designed to ensure medical necessity aligns with clinical guidelines for approved indications such as plaque psoriasis, psoriatic arthritis, and Crohn's disease. Submissions must include comprehensive patient history, prior treatment failures, and supporting clinical documentation. Klivira facilitates the compilation and submission of these critical data points via ePA or X12 278 transactions.
Navigating Step Therapy and Quantity Limits with EmblemHealth
Common step therapy requirements for Skyrizi with EmblemHealth often mandate a documented trial and failure of less costly or alternative therapies, which may include conventional systemic treatments or other biologics, prior to approval. Additionally, quantity limits are typically applied, requiring precise dosing and refill schedules to be justified and approved.
EmblemHealth's PBM Partner and Specialty Pharmacy Routing for Skyrizi
EmblemHealth generally partners with CVS Caremark for its pharmacy benefit management, which dictates the specialty pharmacy network for dispensing medications like Skyrizi. Understanding this PBM relationship is crucial for proper claims routing and ensuring the prescription reaches an in-network specialty pharmacy, avoiding potential delays or denials.
Optimizing the EmblemHealth Skyrizi Prior Authorization Workflow
Manual prior authorization for high-cost specialty drugs like Skyrizi can strain clinic resources. Klivira's platform integrates with EMRs to intelligently gather the necessary clinical data, auto-populate EmblemHealth's specific PA forms, and submit them electronically, significantly reducing turnaround times and administrative overhead. This automation minimizes human error and enhances the predictability of approval cycles.
Frequently asked questions
What is the typical formulary tier for Skyrizi under EmblemHealth?
Skyrizi, as a specialty medication, is generally placed on a higher formulary tier (e.g., Tier 4 or 5) by EmblemHealth. This tiering almost always necessitates a prior authorization, along with potential step therapy and quantity limits, before coverage can be approved.
Does EmblemHealth require step therapy for Skyrizi (risankizumab)?
Yes, EmblemHealth typically requires step therapy for Skyrizi. This usually involves documented evidence of inadequate response or intolerance to prior conventional systemic therapies or other biologics for the approved indications before Skyrizi will be covered.
Which PBM does EmblemHealth use for specialty medications like Skyrizi?
EmblemHealth commonly partners with CVS Caremark as its Pharmacy Benefit Manager (PBM). This partnership means that specialty medications like Skyrizi will be managed through CVS Caremark's formulary and specialty pharmacy network.
How can we check the prior authorization status for Skyrizi with EmblemHealth?
Prior authorization status for EmblemHealth Skyrizi can typically be checked via the payer's provider portal, through an ePA system if submitted electronically, or by contacting the EmblemHealth prior authorization department directly. Klivira's platform can also provide real-time status updates for submissions made through our system.
What documentation is essential for an EmblemHealth Skyrizi prior authorization submission?
Essential documentation for EmblemHealth Skyrizi PA includes patient demographics, diagnosis codes (ICD-10), prescribing physician's notes detailing medical necessity, clinical rationale, past treatment history with outcomes, and any relevant lab results or imaging studies supporting the indication.
Are there quantity limits for Skyrizi under EmblemHealth's plan?
Yes, EmblemHealth typically applies quantity limits to specialty medications like Skyrizi to ensure appropriate utilization and adherence to dosing guidelines. These limits are part of the prior authorization review process and must be justified by the prescribing physician.
Related coverage
Ready to automate prior auth for this plan?
See how Klivira automates prior authorizations for your team.
Request a demo